DNA vs PGEN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

PGEN is the larger of the two ($1.52B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 0.98). DNA is the smaller challenger ($499.42M), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, PGEN fits: analysts expect its revenue to rise 84% next year, against 8% for DNA. If you believe DNA's main driver (AI, autonomous labs, and Datapoints) pays off sooner, DNA fits.

DNA vs PGEN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricDNAPGENWhat it tells you
Market cap$499.42M$1.52BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-2.66-19.27Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.740.98Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range18% of range20% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.2718.12How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how DNA and PGEN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DNA and PGEN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DNA and PGEN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Ginkgo Bioworks Holdings (DNA) do?

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic-biology company built around a horizontal cell-programming platform. Historically it reported in two segments: Cell Engineering, where its automated Foundry labs and Datapoints data service engineer and characterize cells for pharma, agriculture, food, and industrial customers; and Biosecurity, which provided pathogen monitoring and bioinformatics to governments and institutions. Cell Engineering revenue is generated through R&D service fees, its Datapoints biological-data offerings, and design, build, and support fees for its lab-automation (RAC) systems. Ginkgo went public via SPAC in 2021 at a lofty valuation that has since collapsed.

Full DNA guide

What does Precigen (PGEN) do?

Precigen, Inc. is a Maryland-based biopharmaceutical company that develops precision medicines using its proprietary gene- and cell-therapy platforms, most notably the AdenoVerse gorilla-adenovector system, which the FDA has granted platform technology designation. For years it was a clinical-stage, cash-burning research company (formerly Intrexon), but in August 2025 it earned full FDA approval for Papzimeos (zopapogene imadenovec, formerly PRGN-2012), the first approved immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV 6 and 11 in which benign tumors recur in the airway and typically require repeated surgeries. Papzimeos is given as four subcutaneous injections over roughly 12 weeks and is designed to trigger an immune response against HPV-infected cells, and it carries FDA market exclusivity through August 14, 2032. Precigen also runs Exemplar, a small research-models and services business.

Full PGEN guide

DNA vs PGEN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • DNA drivers: AI, autonomous labs, and Datapoints; Cost restructuring toward breakeven.
  • PGEN drivers: Papzimeos launch ramp; From break-even target to profit.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48% and Q3 about 6%), and it is spending down its cash (about $285 million at September 30, 2026, against about $397 million of debt including leases) while promising breakeven that has not yet arrived. For PGEN, pGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once.

DNA or PGEN: which should you pick?

If the story you believe is DNA's (AI, autonomous labs, and Datapoints), DNA is the more direct way to own it; if it is PGEN's (Papzimeos launch ramp), PGEN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DNA and PGEN guides.

DNA vs PGEN: the full fundamentals

DNA. Ginkgo trades at about 3.8 times trailing sales with no earnings, so the valuation rests on whether revenue holds near the Q3 level of about $28 million a quarter and losses keep shrinking. Consensus for Q4 2026 is about $22.8 million of revenue and a loss of about $0.82 per share. The stock is down about 11.5% in 2026 and about 23% over the past month despite the Q3 beat, and sits well below its 52-week high of $18.22. Figures are from Yahoo Finance and company releases as of November 20, 2026; verify live numbers before acting.

PGEN. Precigen moved from commercial launch to two profitable quarters and positive operating cash flow in just over a year, with Q3 2026 revenue of about $74.1 million and net income of about $35.8 million. After a 42% three-month drop the stock trades near 10 times trailing sales and about 38 times trailing earnings, far less stretched than in October, and it still trades on forward launch expectations: consensus revenue of about $240 million in 2026 and $442 million in 2027. The three analysts tracked by Yahoo Finance hold a mean target near $13.67, well above the $4.22 price.

Headline figures (approximate, November 2026): DNA shows revenue (ttm) ~$131 million, with Q3 2026 revenue of ~$27.7 million down ~6% year over year, gross margin ~70%, while operating margin is deeply negative at about -202%, net loss (ttm) ~$277 million; Q3 2026 loss from continuing operations ~$41 million vs ~$73 million a year earlier, adjusted ebitda (q3 2026) ~-$22 million vs ~-$53 million a year earlier; PGEN shows stock price ~$4.22 (Nov 20, 2026); YTD -1%, 1-month -32%, market cap ~$1.5B, revenue (q3 2026 / ttm) ~$74.1M / ~$157M, papzimeos revenue (q3 2026) ~$72.9M, +37% QoQ (~$151M launch to date).

The bottom line: DNA vs PGEN

DNA and PGEN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined DNA and PGEN exposure against your real portfolio. It is not an investment adviser.

Wondering how DNA or PGEN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Ginkgo Bioworks Holdings

Ask Walnut's AI anything about DNA and see how it fits what you own.

FAQ

What is the difference between DNA and PGEN?

+

Ginkgo Bioworks Holdings, Inc. Precigen, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is DNA or PGEN the better stock?

+

Neither is universally better. PGEN is the larger incumbent; DNA is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, DNA or PGEN?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both DNA and PGEN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of DNA vs PGEN?

+

DNA: The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48% and Q3 about 6%), and it is spending down its cash (about $285 million at September 30, 2026, against about $397 million of debt including leases) while promising breakeven that has not yet arrived. If losses persist, further capital raises could dilute existing shareholders, and the company already completed a 1-for-40 reverse split after its post-SPAC valuation collapsed by billions, a reminder of how far expectations have reset. Customer concentration is a concern because a handful of large partners can drive results, and losing or delaying programs hits revenue hard. Competition spans synthetic-biology, lab-automation, and bio-AI players with more focus or funding. Execution risk on the autonomous-lab pivot is high, and the stock is speculative and volatile, so outcomes could be very good or very poor. Wall Street coverage is thin and skeptical: the two analysts in the Yahoo Finance consensus rate it underperform with a mean target near $8, about where the stock closed on November 20 ($7.70) after a 23% drop in a month. PGEN: PGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once. The roughly $1.5 billion market cap still sits well ahead of trailing revenue of about $157 million, so the valuation embeds launch assumptions that leave little margin for disappointment; the shares fell about 32% in the month to November 20, 2026 and about 42% over three months despite a quarter of 37% sequential product growth, which shows how quickly sentiment can swing. Competition is moving closer: on the Q3 call management addressed the prospective launch of Inovio's INO-3107 and said it had planned for competition from the outset, citing payer policies, physician experience and treatment-site capabilities. Cash and investments were about $51 million at September 30, 2026 against about $98.6 million of debt, so a stall in the ramp could still require dilutive financing. The RRP niche, while high-need, is small, and the stock has historically been volatile and heavily shorted.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DNA or PGEN; figures are approximate and dated (as of November 2026). Verify current data before investing.